Protein therapeutics market driven by increased outsourcing of drug development

Press Release   •   Aug 06, 2013 10:41 BST

The protein therapeutics market has been forecast to increase at a compound annual growth rate (CAGR) of 7.08% through to 2016, driven by the increasing prevalence of chronic diseases, and the increasing outsourcing of drug development.

Once a rarely used subset of medical treatments, protein therapeutics have increased dramatically in number and frequency of use since the introduction of the first recombinant protein therapeutic -- human insulin -- 25 years ago.

Despite the post-recessionary impact worldwide causing a major slump in healthcare spending, the protein therapeutics market continues to grow at its retained speed.

Protein therapeutics already have a significant role in almost every field of medicine, but this role is still only in its infancy.

Growth within the protein therapeutics market is set to be predominantly driven by the increase in the prevalence of chronic diseases such as cardiovascular diseases, neuro-degenerative diseases, cancer, diabetes, tuberculosis, HIV, and hepatitis.

Protein therapeutic drugs are more effective in the treatment of these diseases than other pharmaceutical drugs and chemotherapies. Hence, the worldwide increase in the prevalence of chronic diseases is expected to foster the demand for protein therapeutic drugs.

The US holds a dominant position in the global protein therapeutics market as the country provides a major proportion of products' sales. However, the future landscape of the market may find positive developments from the Asian countries as the huge patient population and increasing disposable incomes may turn out to be a win-win condition for industry participants.

Recent analysis has found that a large number of market players have been developing monoclonal antibodies (mAbs)-based therapies. The mAb products contribute one of the largest shares in the number of protein therapeutic products under pipeline.

Key players currently dominating the protein therapeutics market include Roche Holding Ltd., Amgen Inc., Abbott Laboratories, J&J, and Novo Nordisk A/S

For more information on the protein therapeutics market, see the latest research: Protein Therapeutics Market

Follow us on Twitter @CandMResearch issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.